Biobanking Market Size, Share and Forecast 2021-2027
The global biobanking market is anticipated to grow at a considerable CAGR of 6.7% during the forecast period (2021-2027). The market growth is mainly attributed to the rise in cancer patients across the globe leading to an increase in the number of researchers. According to the reports of the World Health Organization, cancer was estimated to be the leading cause of death in 2020 accounting for nearly 10 million deaths across the globe in the same year. Breast cancer was estimated to account for nearly 2.26 million cases and the most common cause of cancer death in 2020 was lung cancer which accounted for around 1.8 million deaths globally. The rise in the number of cancer patients has increased the number of researches to deliver proper treatment. Moreover, collaborations between the private and public institutions have played a vital role in providing growth to the market share. Supportive government initiatives and policies have also contributed to the growth of pharmaceutical biobanks. For instance, in 2018, The Ethics Advisory Committee (EAC) was established to provide advice to the Board on ethical issues that arise during the maintenance, development, and use of the UK Biobank.
To Request a Sample of our Report on Biobanking Market: https://www.omrglobal.com/request-sample/biobanking-market
Moreover, In February 2019, Danaher Corp. announced that it has reached
a definitive agreement with General Electric Co. to buy GE Life Sciences'
Biopharma business ("GE Biopharma") for $21.4 billion. In May 2021,
Vigene Biosciences Inc., a leading U.S.-based gene therapy contract development
and manufacturing organization (CDMO) that specializes in viral vector-based
gene delivery technologies have been acquired by Charles River Laboratories
International Inc. The purchase price was estimated to be roughly $292.5
million.
In January 2019, MediSapiens, a leading developer and provider of genomic, biomedical, and health data solutions, has formed a partnership with Modul-Bio, a leading provider of biological sample management solutions, Biobank Information Management Systems (BIMS), and collaborative tools for sharing biological sample collections. The two companies have done this collaboration with hoping that this commplement one other's biobanking solutions, giving biobanks an all-around capability for managing, exchanging, and commercializing their samples and data. Thus, the rising prevalence of cancer cases, rising demand for the biobanks, and the major player's initiatives such as partnerships, collaborations, and mergers and acquisitions are to drive the market growth during the forecast period.
Market
Coverage
·
The
market number available for – 2020-2027
·
Base
year- 2020
·
Forecast
period- 2021-2027
Segment
Covered-
·
By
Product Type
·
By
Sample Type
·
By
Application
Regions
Covered-
·
North
America
·
Europe
·
Asia-Pacific
·
Rest of
the World
·
Competitive
Landscape- Becton, Dickinson and Co., Thermo Fisher Scientific Inc.,
AstraZeneca plc, Charles River Laboratories, and Boehringer Ingelheim Pharma
GmbH & Co. KG, among others
(Get 15% Discount on Buying this Report)
A
full Report of Biobanking Market is Available at: https://www.omrglobal.com/industry-reports/biobanking-market
Key questions
addressed by the report
·
What is
the market growth rate?
·
Which
segment and region dominate the market in the base year?
·
Which
segment and region will project the fastest growth in the market?
·
How has
COVID-19 impacted the market?
Ø
Deviation
from the pre-COVID-19 forecast
Ø
Most
affected region and segment
·
Who is
the leader in the market?
·
How
players are addressing challenges to sustain growth?
·
Where
is the investment opportunity?
Global
Bio-Banking Market Report Segment
·
Equipment
·
Consumables
·
Software
& Services
By Sample
Type
·
Blood
Products
·
Human
Tissues
·
Nucleic
Acid
·
Cell
Lines
·
Biological
Fluid
·
Human
Waste Product
By
Application
·
Clinical
Research
·
Regenerative
Medicine
Global
Bio-Banking Market Report Segment by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of The World
·
Latin America
·
Middle
East & Africa
Company
Profiles
·
Abbott
Laboratories
·
AstraZeneca
PLC
·
Becton,
Dickinson and Co.
·
BioChain
Institute Inc.
·
Biokryo
GmbH
·
Boehringer
Ingelheim Pharma GmbH & Co. KG
·
Bristol-Myers
Squibb Co.
·
Cell&Co.
·
Charles
River Laboratories International, Inc.
·
Danaher
Corp.
·
F.
Hoffmann-La Roche Ltd.
·
Hamilton
Co.
·
Lonza
Group
·
LVL
Technologies GmbH & Co. KG
·
Merck
KGaA and Co.
·
Micronic
Europe BV
·
Modul-Bio
·
Pfizer
Inc.
·
PromoCell
GmbH
·
QIAGEN
GmbH
·
Tecan
Trading AG
·
Thermo
Fisher Scientific Inc.
·
Ziath
Ltd.
Reasons to Buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More
Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/biobanking-market
About Orion
Market Research
Orion Market Research (OMR) is a market
research and consulting company known for its crisp and concise reports. The
company is equipped with an experienced team of analysts and consultants. OMR
offers quality syndicated research reports, customized research reports,
consulting and other research-based services.
Media Contact:
Company Name: Orion Market
Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment